Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment

Martin W. Schoen, MDMPH, Peter Georgantopoulos, MS, Nagasai S Yalavarthi, BS, Charles L. Bennett, MD PhD

Blood (2019) 134 (Supplement_1): 2135.

https://doi.org/10.1182/blood-2019-121770

Published: 2019

Journal Articles

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Paul G. Richardson, MD, Alessandra Larocca, Xavier Leleu, MD PhD, Albert Oriol, MD, Agne Paner, MD, Paula Rodriguez Otero, Cyrille Touzeau, MD, Adrián Alegre Amor, MD, Christopher Maisel, MD, María-Victoria Mateos, MD PhD, Amitabha Mazumder, MD, Peter Strang, MD, Oskar Öhman, MSc, Johan Harmenberg, MD PhD, Stojan Zavisic, Joan Bladé, MD

Blood (2019) 134 (Supplement_1): 3487.

https://doi.org/10.1182/blood-2019-124832

Published: 2019

Journal Articles

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Scott R. Goldsmith, MD, Sana Saif Ur Rehman, MD, Cara Lunn Shirai, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2325.

https://doi.org/10.1182/blood-2019-124176

Published: 2019

Journal Articles

Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura

Mouhamed Yazan Abou-Ismail, MD, Yasmin Arafah, MD, Pingfu Fu, PhD, Shufen Cao, Alvin H. Schmaier, MD, Lalitha V. Nayak, MD

Blood (2019) 134 (Supplement_1): 1084.

https://doi.org/10.1182/blood-2019-123537

Published: 2019

Journal Articles

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Giovanni Caocci, MD, Martino Deidda, Antonio Noto, Christian Cadeddu, Marianna Greco, Maria Pina Simula, Olga Mulas, Daniele Cocco, Claudia Fattuoni, Giuseppe Mercuro, Giorgio La Nasa

Blood (2019) 134 (Supplement_1): 4144.

https://doi.org/10.1182/blood-2019-124323

Published: 2019

Journal Articles

Comparison of Clinical Evolution of Children with Sickle Cell Disease before and after Treatment with Hydroxyurea at Saint Damien Hospital, Tabarre-Haiti,2013-2018

Nora St Victor Dély, MD, Ofelia A. Alvarez, MD, Vanessa J Dor, MD, Emmeline Lerebours, MD

Blood (2019) 134 (Supplement_1): 2306.

https://doi.org/10.1182/blood-2019-124105

Published: 2019

Journal Articles

Bone Marrow T Cell Changes By Multiplex IHC after Treatment with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Protein, in a Primary Refractory t-AML Patient

John Godwin, MD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Helene Lelièvre, PhD PharmD, Jon Wigginton, MD, Jan K Davidson-Moncada, MD PhD, Bernard Fox, PhD

Blood (2018) 132 (Supplement 1): 4065.

https://doi.org/10.1182/blood-2018-99-118522

Published: 2018

Journal Articles

Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study

Dae Young Zang, MD PhD, Won Sik Lee, MD PhD, Yeung-Chul Mun, Young Rok Do, PhD MD, Sukjoong Oh, MD PhD, Sung-Eun Lee, MD PhD, Soo Young Choi, Dong-Wook Kim, MD PhD

Blood (2018) 132 (Supplement 1): 4252.

https://doi.org/10.1182/blood-2018-99-118026

Published: 2018

Journal Articles

Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment

Mirela Anghelina, Narendranath Epperla, MD MS, Kerry A. Rogers, MD, Ling Guo, MD, Qiuhong Zhao, MS, James S. Blachly, MD, David M. Lucas, PhD, Christopher C. Oakes, Gerard Lozanski, MD, Michael R. Grever, MD, Leslie A. Andritsos, MD

Blood (2018) 132 (Supplement 1): 4143.

https://doi.org/10.1182/blood-2018-99-120043

Published: 2018

Journal Articles

Prognostic Value of Circulating Bcl-2/Igh Levels before and after Treatment in 415 Patients with Advanced Follicular Lymphoma Receiving First-Line Immuno-Chemotherapy in 2 Prospective StiL Trials - the Effect of Rituximab Maintenance

Guido Kobbe, Sabrina Pechtel, Fabian Zohren, MD PhD, Jürgen Barth, Alexander Christoph Burchardt, MD, Christian Buske, MD, Ariane Dienst, MD, Ulrich Germing, MD, Richard Greil, MD, Bernd Hertenstein, MD, Frank Kauff, Michael Koenigsmann, MD, Christian Lerchenmüller, MD, Thomas Michael Schroeder, MD PhD, Rainer Haas, MD, Mathias J Rummel, MD PhD

Blood (2018) 132 (Supplement 1): 4149.

https://doi.org/10.1182/blood-2018-99-118750

Published: 2018

Journal Articles

Outcomes in Children with Severe Vasculopathy from Sickle Cell Anemia after Treatment with Chronic Transfusion, Surgical Revascularization and/or Allogenic Hematopoetic Stem Cell Transplantation

Courtney W. Johnson, MD MSc, Suvankar Majumdar, MBCHB, Andrew D. Campbell, MD, Suresh Magge, MD, Deepika S. Darbari, MD, Jennifer Webb, MD, Yaser A. Diab, MBBS, Robert Sheppard Nickel, MDMSc, Barbara Speller-Brown, DNP, CPNP-BC, Jessica Carpenter, MD, Allistair Abraham, MD

Blood (2018) 132 (Supplement 1): 1098.

https://doi.org/10.1182/blood-2018-99-118693

Published: 2018

Journal Articles

Patterns of Care of Diffuse Large B Cell Lymphoma Patients 80 Years and Older: Worse Outcomes after Treatment without Increased Relapse

Madison Keenan, Kirsten Marie Boughan, DO, Brenda Cooper, MD, Molly M Gallogly, MDPhD, Stanton L. Gerson, MD, Hillard M Lazarus, MD, Ehsan Malek, MD, Leland Metheny, MD, Folashade Otegbeye, MBBChir, MPH, Benjamin K. Tomlinson, MD, Erika Moore, MD, Kwadwo Asare Oduro, MD PhD, Rose Beck, MD PhD, Howard Meyerson, MD, Marcos de Lima, MD, Paolo F Caimi, MD

Blood (2018) 132 (Supplement 1): 575.

https://doi.org/10.1182/blood-2018-99-117587

Published: 2018

Journal Articles

Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate

Armando Santoro, MD, Luca Castagna, MD, Massimo Magagnoli, MD, Stefania Bramanti, MD, Jacopo Mariotti, MD, Rita Mazza, MD, Lucia Morello, MD, Francesca Ricci, MD, Barbara Sarina, MD, Chiara De Philippis, MD, Simona Sica, MD, Marcello Rodari, MD, Martina Sollini, MD, Margarita Kirienko, MD, Laura Giordano, Arturo Chiti, MD, Paolo Corradini, MD, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2018-99-118127

Published: 2018

Journal Articles

Chronic Severe Pain and Use of Prescription Pain Medications in Older Survivors of Hematologic Malignancies (HM) Several Years after Treatment with Blood or Marrow Transplantation (BMT): A Report from BMTSS

Naveed Farrukh, Lindsey Hageman, MPH, Yanjun Chen, MS, Jessica Wu, MPH, Emily Ness, MPH, Liton F. Francisco, BS, Mariel Parman, MPH, Wendy Landier, PhD CRNP, Mukta Arora, MD, Saro H. Armenian, DO, MPH, Grant R Williams, Smita Bhatia, MD MPH

Blood (2018) 132 (Supplement 1): 715.

https://doi.org/10.1182/blood-2018-99-111500

Published: 2018

Journal Articles

Addition of Venetoclax to Patients with Acute Myeloid Leukemia Relapsing after Treatment with Hypomethylating Agents. Multicenter Historical Prospective Study

Ron Ram, MD, Odelia Amit, MD, Tsila Zuckerman, MD, Ronit Gurion, Pia Raanani, Yael Bar-On, MD, Irit Avivi, MD, Ofir Wolach, MD

Blood (2018) 132 (Supplement 1): 4046.

https://doi.org/10.1182/blood-2018-99-113596

Published: 2018

Journal Articles

Apoptosis Induction and Cell Cycle Profiling after Treatment with Low-Dose Decitabine and/or Bortezomib in the AML Cell Line Kasumi-1

Vassiliki Mpakou, PhD, Aris Spathis, PhD, Athanassios Velentzas, PhD, Frieda Kontsioti, PhD, Anthi Bouhla, MD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Irene Glezou, MD, Sotirios Papageorgiou, MD PhD, Efthimia Bazani, MD, Diamantina Vasilatou, MD, Argiris Symeonidis, MD PhD, George Dimitriadis, MD, Vassiliki Pappa, MD

Blood (2017) 130 (Supplement 1): 4994.

https://doi.org/10.1182/blood.V130.Suppl_1.4994.4994

Published: 2017

Journal Articles

The Outcome of Patients with High Risk MDS Achieving Stable Disease after Treatment with 5- Azacitidine. A Retrospective Analysis of the Hellenic (Greek) Mds Study Group

Sotirios Papageorgiou, MD PhD, Christos K. Kontos, PhD, Thomas Tsiambalis, Athina Vyniou, Argiris Symeonidis, MD PhD, Athanasios Galanopoulos, MD PhD, Ioannis Kotsianidis, PhD, Vassiliki Pappa, MD

Blood (2017) 130 (Supplement 1): 1693.

https://doi.org/10.1182/blood.V130.Suppl_1.1693.1693

Published: 2017

Journal Articles

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017

Tanya Siddiqi, MD, Jeremy S. Abramson, MD MMSc, Daniel Li, PhD, William Brown, MAS, Todd Devries, PhD, Kedar Dave, PhD, Jacob Garcia, MD, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, BS, Andres Forero-Torres, MD, David G. Maloney, MD PhD, Tina Albertson, MD, Claire L Sutherland, PhD

Blood (2017) 130 (Supplement 1): 193.

https://doi.org/10.1182/blood.V130.Suppl_1.193.193

Published: 2017

Journal Articles

Social Support Source and Effectiveness Are Associated with Distress Among Hematopoietic Stem Cell Transplant Survivors Experiencing Stress Due to Negative Life Events after Treatment

Christine Rini, PhD, Marjorie Margolis, MSPH, Jane Austin, PhD, Heiddis Valdimarsdottir, PhD, Lisa Wu, PhD, Annette Stanton, PhD, Scott D. Rowley, MD

Blood (2017) 130 (Supplement 1): 2164.

https://doi.org/10.1182/blood.V130.Suppl_1.2164.2164

Published: 2017

Journal Articles

TP53 , ETV6 and RUNX1 Germline Variants in Patients Developing Secondary Neoplasms after Treatment for Childhood Acute Lymphoblastic Leukemia

Stefanie V. Junk, PhD, Norman Klein, Sabine Schreek, Martin Zimmermann, PhD, Anja Möricke, MD, Kirsten Bleckmann, Gunnar Cario, MD, Martin Schrappe, MD PhD, Christian P. Kratz, MD, Martin Stanulla, MD PhD

Blood (2017) 130 (Supplement 1): 884.

https://doi.org/10.1182/blood.V130.Suppl_1.884.884

Published: 2017

NARROW

Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Comparison of Clinical Evolution of Children with Sickle Cell Disease before and after Treatment with Hydroxyurea at Saint Damien Hospital, Tabarre-Haiti,2013-2018

Bone Marrow T Cell Changes By Multiplex IHC after Treatment with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Protein, in a Primary Refractory t-AML Patient

Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study

Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment

Prognostic Value of Circulating Bcl-2/Igh Levels before and after Treatment in 415 Patients with Advanced Follicular Lymphoma Receiving First-Line Immuno-Chemotherapy in 2 Prospective StiL Trials - the Effect of Rituximab Maintenance

Outcomes in Children with Severe Vasculopathy from Sickle Cell Anemia after Treatment with Chronic Transfusion, Surgical Revascularization and/or Allogenic Hematopoetic Stem Cell Transplantation

Patterns of Care of Diffuse Large B Cell Lymphoma Patients 80 Years and Older: Worse Outcomes after Treatment without Increased Relapse

Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate

Chronic Severe Pain and Use of Prescription Pain Medications in Older Survivors of Hematologic Malignancies (HM) Several Years after Treatment with Blood or Marrow Transplantation (BMT): A Report from BMTSS

Addition of Venetoclax to Patients with Acute Myeloid Leukemia Relapsing after Treatment with Hypomethylating Agents. Multicenter Historical Prospective Study

Apoptosis Induction and Cell Cycle Profiling after Treatment with Low-Dose Decitabine and/or Bortezomib in the AML Cell Line Kasumi-1

The Outcome of Patients with High Risk MDS Achieving Stable Disease after Treatment with 5- Azacitidine. A Retrospective Analysis of the Hellenic (Greek) Mds Study Group

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017

Social Support Source and Effectiveness Are Associated with Distress Among Hematopoietic Stem Cell Transplant Survivors Experiencing Stress Due to Negative Life Events after Treatment

TP53 , ETV6 and RUNX1 Germline Variants in Patients Developing Secondary Neoplasms after Treatment for Childhood Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only